Moreover, bile acid receptor GP-BAR1 (TGR5) expression has been shown to be increased in rodent models of colitis and Crohn’s disease (22); and the treatment of a murine model of non-alcoholic fatty liver disease with a dual bile acid FXR/TGR5 receptor agonist was shown to decrease intrahepatic inflammation and altered the immune phenotype of monocytes (23). Here, GPBAR1 is linked to Crohn disease.